AIM ImmunoTech Inc. (AIM) — Stock Valuation & Research

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its…

AIM key statistics

Price$0.16
Market cap$6.49M
SectorHealthcare
IndustryBiotechnology
ExchangeAMEX
52-week range0.15-1.95926
Beta1.31

Explore AIM's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.